Amplyx Pharmaceuticals (United States)

Recent papers from Amplyx Pharmaceuticals (United States)

1. Phase II trial of sodium phenylbutyrate and taurursodiol in Wolfram syndrome.2026
2. Phosphorylated Tau at Threonine 181 Is Elevated in Amyotrophic Lateral Sclerosis PlasmaMuscle & Nerve · 2026
3. High-purity amplification of circularly polarized orbital angular momentum modes in an active spun ring-core tapered fiber [Invited]Optical Materials Express · 2026
4. Real‐World Clinical Experience With Sodium Phenylbutyrate and Taurursodiol at a Single Amyotrophic Lateral Sclerosis Center in the United StatesEuropean Journal of Neurology · 2025
5. Fosmanogepix for the Treatment of Invasive Mold Diseases Caused by Aspergillus Species and Rare Molds: A Phase 2, Open-Label Study (AEGIS)Clinical Infectious Diseases · 2025
6. B-225 Bridging the Gap Between Clinical Microbiology and Molecular Diagnostics: Correlation of PCR Cycle Threshold Values for Establishing Semi-Quantitative CFU/mL Ranges of Bacterial TargetsClinical Chemistry · 2024
7. Yb-doped tapered double-clad fibers with polarization maintenance for half-kW power amplifiersOptics Express · 2024
8. A phase 1 open label study to assess the human mass balance and metabolite profile of ¹⁴ C-fosmanogepix, a novel Gwt-1 inhibitor in healthy male participantsAntimicrobial Agents and Chemotherapy · 2024
9. Nonclinical and clinical characterization of MAU868, a novel human-derived monoclonal neutralizing antibody targeting BK polyomavirus VP1American Journal of Transplantation · 2024
10. Biological effects of sodium phenylbutyrate and taurursodiol in Alzheimer's diseaseAlzheimer s & Dementia Translational Research & Clinical Interventions · 2024
11. Phase 1 drug-drug interaction study to assess the effect of CYP3A4 inhibition and pan-CYP induction on the pharmacokinetics and safety of fosmanogepix in healthy participantsAntimicrobial Agents and Chemotherapy · 2024
12. Clinician Education Initiatives for General Neurologists on ALS: Why It Is Needed and ThinkALS, a Possible Solution (P5-11.008)Neurology · 2024
13. Pharmacokinetics, safety, and tolerability of fosmanogepix IV to oral switch and multiple IV doses in healthy participantsAntimicrobial Agents and Chemotherapy · 2024
14. Effect of sodium phenylbutyrate and taurursodiol on plasma concentrations of neuroinflammatory biomarkers in amyotrophic lateral sclerosis: results from the CENTAUR trialJournal of Neurology Neurosurgery & Psychiatry · 2023
15. Double-clad ytterbium-doped tapered fiber with circular birefringence as a gain medium for structured lightOptics Letters · 2023
16. Phase 1b safety and pharmacokinetics of intravenous and oral fosmanogepix in patients with acute myeloid leukaemia and neutropeniaJournal of Antimicrobial Chemotherapy · 2023
17. Clinical safety and efficacy of novel antifungal, fosmanogepix, for the treatment of candidaemia: results from a Phase 2 trialJournal of Antimicrobial Chemotherapy · 2023
18. Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris : Results from a Phase 2 TrialAntimicrobial Agents and Chemotherapy · 2023
19. Safety and Pharmacokinetics of Intravenous and Oral Fosmanogepix, a First-in-Class Antifungal Agent, in Healthy VolunteersAntimicrobial Agents and Chemotherapy · 2023
20. Efficacy of ceftazidime in a murine model following a lethal aerosol exposure to Burkholderia pseudomalleiScientific Reports · 2023